Polymyalgia rheumatica and vertebral fractures: a 1-year pilot controlled study

Area of Science:

• Rheumatology
• Clinical Medicine
• Epidemiology

Background:

• Polymyalgia rheumatica (PMR) is an inflammatory condition often treated with corticosteroids.
• The relationship between vertebral fractures (VF) and steroid therapy in PMR patients is not fully understood.
• Investigating VF independent of steroid therapy is crucial for comprehensive patient management.

Purpose of the Study:

• To investigate the possibility of vertebral fractures occurring independently of steroid therapy in polymyalgia rheumatica patients.
• To identify potential predictors of vertebral fractures in this patient population.
• To analyze clinical and laboratory parameters associated with vertebral fractures in PMR.

Main Methods:

• A case cohort study design with a 1-year follow-up was employed.
• Ten consecutive PMR patients with vertebral fractures (VF-group) and ten controls without fractures were selected.
• Erythrocyte sedimentation rate (ESR), visual analog scale (VAS) scores, and methyprednisolone dosage were monthly evaluated.

Main Results:

• The VF-group received a statistically significant higher total corticosteroid dosage over 12 months.
• Patients with vertebral fractures exhibited significantly higher ESR and VAS area under the curve (AUC) compared to controls.
• Baseline ESR (>80 mm) and VAS difference (1st-2nd month, <=3) showed high specificity and sensitivity for predicting vertebral fractures.

Conclusions:

• Vertebral fractures in PMR patients may not solely be a consequence of steroid therapy.
• Elevated ESR and VAS scores are significant predictors of vertebral fractures in PMR.
• Commonly used laboratory (ESR) and clinical (VAS) findings can help predict vertebral fractures in PMR patients.